Evidence map›Paper›PMID 42286270›Full record

ArticleNature chemical biology2026

Atomic-level protein-ligand recognition with PBCNet2.0 for probe discovery.

Jie Yu, Xia Sheng, Zhehuan Fan, Zhaokun Wang, Duanhua Cao, Yufan Tang, Yongxin Hao, Yingying Zhang, Panpan Shao, Huicong Ma and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A dual assault on KRAS.Nature chemical biology · 2026
    Article
  2. AI decodes protein-ligand binding.Nature chemical biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jie YuDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xia ShengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zhehuan FanDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Zhaokun WangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Duanhua CaoSchool of Life Sciences and Technology, Tongji University, Shanghai, China.
Yufan TangFudan University, Shanghai, China.
Yongxin HaoDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yingying ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Panpan ShaoDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Huicong MaSchool of Pharmacy, Zunyi Medical University, Zunyi, China.
Tian CaoZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan Tsuihang New District, Guangdong, China.
Chuanlong ZengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
JingXin RaoDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mingan ChenDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Kaixian ChenDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xutong LiDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0001-9547-0643
Dan TengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Xiaomin LuoDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Mingliang WangSchool of Pharmacy, Zunyi Medical University, Zunyi, China. wangmingliang@simm.ac.cn.ORCID http://orcid.org/0000-0002-3834-3784
Sulin ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. slzhang@simm.ac.cn.ORCID http://orcid.org/0000-0002-9167-4689
Mingyue ZhengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. myzheng@simm.ac.cn.ORCID http://orcid.org/0000-0002-3323-3092

Funding

National Natural Science Foundation of China (National Science Foundation of China) T2225002,82273855
6 · The paper itself

Abstract

Accelerating molecular probe discovery and lead optimization requires accurate and efficient binding affinity prediction. Here we present PBCNet2.0, a Cartesian tensor-based Siamese neural network for protein-ligand relative binding affinity prediction. Trained on 8.6 million protein-ligand complex pairs, PBCNet2.0 achieves zero-shot accuracy similar to computationally intensive physics-based simulations while remaining highly efficient. Retrospective prioritization experiments show that PBCNet2.0 improves optimization efficiency by 7.18-fold and reduces resource use by 41%. Mechanistic analyses indicate that the model captures intermolecular interactions and encodes spatial geometric constraints, enabling sensitivity to subtle effects such as fluorine orthogonal multipolar interactions. Notably, although not trained on mutation data, PBCNet2.0 exhibits an emergent capability to predict affinity changes induced by binding pocket residue variations, supporting resistance analysis. We prospectively validated these capabilities on ENPP1 and ALDH1B1, accurately resolving affinity shifts from minor interaction and conformational differences and identifying critical binding residues with a hit rate of five out of six selected residues.

Indexed as

Drug DiscoveryMolecular ProbesNeural Networks, ComputerProteinsBinding SitesLigandsModels, MolecularPhosphoric Diester HydrolasesProtein BindingProtein ConformationLigandsMolecular ProbesPhosphoric Diester HydrolasesProteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.